Recursion Pharmaceuticals reports fourth-quarter and full-year 2025 results Wednesday before the market opens, with investors scrutinizing whether the AI-driven biotech can translate its massive data ...

The consensus estimate for Q4 2025 revenue is $24.59 million, and the earnings are expected to come in at -$0.27 per share. The full year 2025's revenue is expected to be $61.58 million and the ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the AI stocks that will go to the moon. On February 18, Recursion ...

NVIDIA’s most recent 13F filing showed no position in Recursion Pharmaceuticals, indicating a complete exit from its previous ...

Recursion Pharmaceuticals Inc RXRX shares are under pressure Wednesday after new regulatory filings showed that Nvidia Corp NVDA has fully exited its investment in the AI‑focused drug‑discovery ...

RXRX gears up for Q4 with $25.5 million revenue view as investors eye pipeline updates and REC-4881 progress ahead of FDA ...

Recursion will host a (L)earnings Call on February 25, 2026 at 8:00 am ET / 6:00 am MT / 1:00 pm GMT. The company will broadcast the live stream from Recursion’s X, LinkedIn, and YouTube accounts.

Ark Invest added to three positions that are well below last year's highs.

Recursion, Inc（共同創業者：田島慎也、Jeffry Alvarado、本社：アメリカカリフォルニア州）が運営するコンピュータサイエンス学習サイト「Recursion」は、技術の進歩と共に日々変化するバックエンドエンジニアの分野に焦点を当てた、新しい学習ロードマップの ...

現役シリコンバレーエンジニア監修のコンピュータサイエンス学習プラットフォーム「Recursion」を提供するRecursion, Inc（本社：カリフォルニア州シリコンバレー、共同創業者：田島慎也 、Jeffry Alvarado、以下当社）は、2021年4月24日、ユーザーの総提出コード数 ...